{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:37:08Z","timestamp":1785854228388,"version":"3.56.0"},"reference-count":46,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Kidney EGFR expression together with reported cases of glomerular diseases in the context of anti-EGFR drug administration raise concerns about the renal safety profile of these drugs. This issue is addressed in a case\/non-case study carried out on VigiBase\u00ae, the WHO global database of individual case safety reports (ICRS). Disproportionality analysis of renal adverse effects related to the selected anti-EGFR drugs, erlotinib, gefitinib, afatinib, osimertinib, cetuximab and panitumumab, was assessed using the reporting odds ratio (ROR). Nine hundred and eighty-nine ICRSs were included. A signal of disproportionate reporting (SDR) was found for afatinib (ROR = 2.70; 95% CI [2.22\u20133.29]) and erlotinib (ROR = 1.73; 95% CI [1.46\u20132.04]) with acute kidney injury, and for afatinib (ROR = 2.41; 95% CI [1.78\u20133.27]), cetuximab (ROR = 1.42; 95% CI [1.14\u20131.78]) and erlotinib (ROR = 2.23; 95% CI [1.80\u20132.77]) with renal failure. The preferred term \u201cdiarrhoea\u201d was frequently reported in the included cases. An SDR was found for erlotinib with haemolytic and uremic syndrome (ROR = 4.01; 95% CI [1.80\u20138.94]) and thrombotic microangiopathy (ROR = 4.94; 95% CI [2.80\u20138.72]). No SDR was seen for glomerular or tubule-interstitial diseases. This study showed that the anti-EGFR drug renal toxicity is mainly related to renal failure in the context of digestive toxicity.<\/jats:p>","DOI":"10.3390\/cancers13235907","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T04:01:28Z","timestamp":1637812888000},"page":"5907","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Renal Safety Profile of EGFR Targeted Therapies: A Study from VigiBase\u00ae the WHO Global Database of Individual Case Safety Reports"],"prefix":"10.3390","volume":"13","author":[{"given":"Alexandre","family":"Crosnier","sequence":"first","affiliation":[{"name":"Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, 4 Rue Larrey, 49100 Angers, France"},{"name":"D\u00e9partement de M\u00e9decine, Facult\u00e9 de M\u00e9decine d\u2019Angers, Universit\u00e9 d\u2019Angers, 49035 Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Abbara","sequence":"additional","affiliation":[{"name":"Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, 4 Rue Larrey, 49100 Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Cellier","sequence":"additional","affiliation":[{"name":"Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, 4 Rue Larrey, 49100 Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7609-6972","authenticated-orcid":false,"given":"Laurence","family":"Lagarce","sequence":"additional","affiliation":[{"name":"Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, 4 Rue Larrey, 49100 Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Babin","sequence":"additional","affiliation":[{"name":"Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, 4 Rue Larrey, 49100 Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Bourneau-Martin","sequence":"additional","affiliation":[{"name":"Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, 4 Rue Larrey, 49100 Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3738-5998","authenticated-orcid":false,"given":"Marie","family":"Briet","sequence":"additional","affiliation":[{"name":"Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, 4 Rue Larrey, 49100 Angers, France"},{"name":"D\u00e9partement de M\u00e9decine, Facult\u00e9 de M\u00e9decine d\u2019Angers, Universit\u00e9 d\u2019Angers, 49035 Angers, France"},{"name":"Research Institute MitoVasc, UMR CNRS 6214 INSERM 1083, University of Angers, 49100 Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1158\/1078-0432.CCR-05-1554","article-title":"The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy","volume":"12","author":"Scaltriti","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_2","unstructured":"(2021, May 24). Food and Drug Administration FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm."},{"key":"ref_3","unstructured":"(2021, May 24). European Medicines Agency Medicines. Available online: https:\/\/www.ema.europa.eu\/en\/medicines."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.tips.2019.10.004","article-title":"A Third Shot at EGFR: New Opportunities in Cancer Therapy","volume":"40","author":"Guardiola","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.21037\/tcr.2018.10.06","article-title":"EGFR first- and second-generation TKIs\u2014There is still place for them in EGFR-mutant NSCLC patients","volume":"8","author":"Karachaliou","year":"2018","journal-title":"Transl. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12943-018-0778-0","article-title":"Third generation EGFR TKIs: Current data and future directions","volume":"17","author":"Tan","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00018-008-7440-8","article-title":"The epidermal growth factor receptor family: Biology driving targeted therapeutics","volume":"65","author":"Wieduwilt","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1126\/science.286.5443.1358","article-title":"Cell Survival Promoted by the Ras-MAPK Signaling Pathway by Transcription-Dependent and -Independent Mechanisms","volume":"286","author":"Bonni","year":"1999","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.drup.2007.11.003","article-title":"Targeting the PI3K\/Akt\/mTOR pathway: Effective combinations and clinical considerations","volume":"11","author":"LoPiccolo","year":"2008","journal-title":"Drug Resist. Updat."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nrd1902","article-title":"Exploiting the PI3K\/AKT Pathway for Cancer Drug Discovery","volume":"4","author":"Hennessy","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1016\/j.ejca.2006.07.006","article-title":"JAK\/STAT signalling pathway in colorectal cancer: A new biological target with therapeutic implications","volume":"42","author":"Spano","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"567486","DOI":"10.1155\/2009\/567486","article-title":"Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers","volume":"2009","author":"Harandi","year":"2009","journal-title":"J. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jtho.2016.11.2236","article-title":"Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR -Mutated Non\u2013Small Cell Lung Cancer","volume":"12","author":"Lord","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in Previously Treated Non\u2013Small-Cell Lung Cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the Treatment of Colorectal Cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"LBA7500","DOI":"10.1200\/jco.2012.30.18_suppl.lba7500","article-title":"LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations","volume":"30","author":"Yang","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1634\/theoncologist.2008-0254","article-title":"FDA Review of a Panitumumab (Vectibix\u2122) Clinical Trial for First-Line Treatment of Metastatic Colorectal Cancer","volume":"14","author":"Giusti","year":"2009","journal-title":"Oncologist"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1074\/mcp.M113.035600","article-title":"Analysis of the Human Tissue-specific Expression by Genome-wide Integration of Transcriptomics and Antibody-based Proteomics","volume":"13","author":"Fagerberg","year":"2014","journal-title":"Mol. Cell. Proteom."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Tissue-Based Map of the Human Proteome","volume":"347","author":"Fagerberg","year":"2015","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/ki.1996.94","article-title":"Expression of epidermal growth factor and its receptor in normal and diseased human kidney: An immunohistochemical and in situ hybridization study","volume":"49","author":"Gesualdo","year":"1996","journal-title":"Kidney Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.trim.2004.05.001","article-title":"Epidermal growth factor receptor expression in human renal allograft biopsies: An immunohistochemical study","volume":"13","author":"Sis","year":"2004","journal-title":"Transpl. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nephro.2019.06.003","article-title":"Toxicit\u00e9s r\u00e9nales des th\u00e9rapies cibl\u00e9es en oncologie","volume":"16","author":"Izzedine","year":"2020","journal-title":"N\u00e9phrologie Th\u00e9rapeutique"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/ndt\/gfw467","article-title":"Adverse kidney effects of epidermal growth factor receptor inhibitors","volume":"32","author":"Izzedine","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40620-016-0311-8","article-title":"Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs)","volume":"30","author":"Cosmai","year":"2016","journal-title":"J. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ekir.2016.09.055","article-title":"Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review","volume":"2","author":"Jhaveri","year":"2016","journal-title":"Kidney Int. Rep."},{"key":"ref_28","unstructured":"World Health Organization (2021, April 28). What Is VigiBase?. Available online: https:\/\/www.who-umc.org\/vigibase\/vigibase\/."},{"key":"ref_29","unstructured":"World Health Organization (2021, April 28). Open Access to the WHO Global Pharmacovigilance Data Base. Available online: https:\/\/www.who.int\/medicines\/news\/glob_pharmvig_database_qa\/en\/."},{"key":"ref_30","first-page":"409","article-title":"VigiBase, the WHO Global ICSR Database System: Basic Facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_31","unstructured":"(2021, April 28). International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Welcome to the ICH MedDRA Website. Available online: https:\/\/www.meddra.org\/how-to-use\/support-documentation\/english\/welcome."},{"key":"ref_32","unstructured":"World Health Organization (2021, May 05). VigiMethods. Available online: https:\/\/www.who-umc.org\/vigibase\/vigilyze\/vigimethods\/."},{"key":"ref_33","unstructured":"European Medicines Agency (2016). Screening for Adverse Reactions in EudraVigilance, European Medicines Agency."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.therap.2017.08.006","article-title":"Les \u00e9tudes cas\u2013non cas: Principe, m\u00e9thodes, biais et interpr\u00e9tations","volume":"73","author":"Faillie","year":"2018","journal-title":"Therapies"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/gut.39.2.262","article-title":"The epidermal growth factor receptor (EGF-R) is present on the basolateral, but not the apical, surface of enterocytes in the human gastrointestinal tract","volume":"39","author":"Playford","year":"1996","journal-title":"Gut"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ctrv.2015.05.011","article-title":"ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: Chloride secretion as a mechanistic hypothesis","volume":"41","author":"Gibson","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10549-018-05102-x","article-title":"The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea","volume":"175","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e14490","DOI":"10.14814\/phy2.14490","article-title":"Potentiation of calcium-activated chloride secretion and barrier dysfunction may underlie EGF receptor tyrosine kinase inhibitor-induced diarrhea","volume":"8","author":"Kim","year":"2020","journal-title":"Physiol. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bulcan.2015.09.011","article-title":"La voie de signalisation PI3K-AKT-mTOR: Description, d\u00e9veloppement th\u00e9rapeutique, r\u00e9sistances, marqueurs pr\u00e9dictifs\/pronostiques et applications th\u00e9rapeutiques en canc\u00e9rologie","volume":"103","author":"Brotelle","year":"2016","journal-title":"Bull Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.onc.1205260","article-title":"Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis","volume":"21","author":"Niu","year":"2002","journal-title":"Oncogene"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11912-012-0242-z","article-title":"VEGF Inhibition, Hypertension, and Renal Toxicity","volume":"14","author":"Hayman","year":"2012","journal-title":"Curr. Oncol. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/HYPERTENSIONAHA.116.07618","article-title":"Mechanisms of Hypertension and Renal Injury During Vascular Endothelial Growth Factor Signaling Inhibition","volume":"68","author":"Meiracker","year":"2016","journal-title":"Hypertension"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/ndt\/gfs030","article-title":"Epidermal growth factor: A new therapeutic target in glomerular disease","volume":"27","author":"Flamant","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_45","first-page":"8739473","article-title":"Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage","volume":"2018","author":"Valentijn","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","article-title":"Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"16","author":"Alatawi","year":"2017","journal-title":"Expert Opin. Drug Saf."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/23\/5907\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:35:09Z","timestamp":1760168109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/23\/5907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":46,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["cancers13235907"],"URL":"https:\/\/doi.org\/10.3390\/cancers13235907","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,24]]}}}